

Interim Report

Quarter 1, 2026



Good start to 2026 – increased volumes and higher margins

Quarter 1, 2026

- Net sales decreased 5.1% to SEK 33,177m (34,976). Excluding currency translation effects, net sales increased SEK 528m.
- Organic sales growth amounted to 0.4%, of which volume accounted for 1.1% and price/mix -0.7%
- The acquisition of Edgewell's feminine care business in North America was completed and consolidated as of February 2, 2026. The acquisition increased the Group's net sales by 1.1%.
- EBITA decreased 6% to SEK 4,448m (4,718)
- EBITA excl. IAC decreased 2% to SEK 4,603m (4,706). Excluding currency translation effects, EBITA excl. IAC increased 5%, corresponding to SEK 236m.
- EBITA margin excl. IAC increased 0.4 percentage points to 13.9% (13.5)
- ROCE amounted to 15.8% (16.7) and ROCE excl. IAC was 16.3% (16.7)
- Profit for the period was SEK 2,901m (3,083)
- Earnings per share were SEK 4.23 (4.43)
- After the end of the first quarter, it was announced that Essity's Board of Directors had resolved on a new share buyback program for SEK 3bn commencing no earlier than May 11, 2026.

0.4%

Organic sales growth

13.9%

EBITA margin excl. IAC

Financial overview

	2026:1	2025:1	%
Net sales, SEKm	33,177	34,976	-5
Organic sales growth, %	0.4	2.1	
Gross profit margin, %	33.5	32.8	
Gross profit margin excl. IAC, %	33.4	32.8	
EBITA, SEKm	4,448	4,718	-6
EBITA margin, %	13.4	13.5	
EBITA excl. IAC, SEKm	4,603	4,706	-2
EBITA margin excl. IAC, %	13.9	13.5	
Profit for the period, SEKm	2,901	3,083	-6
Earnings per share, SEK	4.23	4.43	-4
Earnings per share ¹⁾ , SEK	4.70	4.65	1
ROCE, %	15.8	16.7	
ROCE excl. IAC, %	16.3	16.7	
Operating cash flow, SEKm	4,354	3,765	16
Net debt/EBITDA excl. IAC	0.96	1.02	

¹⁾ Earnings per share excl. IAC and amortization of acquisition-related intangible assets



CEO'S comments

We started 2026 with a positive volume trend, increased market shares and higher margins. At the same time, we continued our efforts to accelerate growth, including the completion of the Feminine Care acquisition in North America, several product launches and the implementation of our organizational change. In this quarter we thereby report on the basis of our four new business areas for the first time.



Positive volume trend

We delivered positive organic sales growth for the quarter related to higher volumes. For the new Personal Care business area, we captured market shares and sales performed strongly, fueled by continued high growth in

Incontinence Products and Feminine Care. In Professional Hygiene, we could see the effects of our actions to drive volume which – combined with a somewhat more stable market in North America – yielded volume-related growth. Health & Medical also reported positive growth, supported by a good sales trend in Medical Solutions. Consumer Tissue noted a decline in sales, partly due to lower sales in Private Label. However, our own brands once again performed well this quarter.

Higher margins

The gross margin increased as a result of higher volumes, lower costs of goods sold and good price discipline. Total sales and administration costs were slightly higher, and included an increased marketing spend to support growth. In summary, the EBITA margin excl. IAC increased year on year.

Product launches

Our launches during the quarter reflect our focus on innovation, and our ambition to continue strengthening our leading positions. We launched an even softer Libero baby diaper, upgraded parts of our North American TENA range, and introduced coreless household towels under the Zewa brand in Germany. In Feminine Care, we strengthened our offering in the rapidly growing segment “period pants” with a range specially designed for teenagers.

Acquisition in North America completed

The acquisition of Edgewell’s feminine care business in North America was completed during the quarter. We look forward to accelerating the growth and profitability of the Carefree, Stayfree, Playtex and o.b. brands, based on our established recipe for success that comprises

high-impact innovation combined with effective marketing. The acquisition is aligned with our ambition to grow in categories that yield a high return in attractive markets and nearly doubles our presence in Personal Care in North America.

Strong balance sheet and new share buyback program

We reported higher operating cash flow for the quarter and we further strengthened our balance sheet. The Board of Directors has approved a new share buyback program commencing in May and amounting to SEK 3bn.

A turbulent external environment

Considerable geopolitical turbulence dominated the first quarter of 2026. We have a broad range of leading hygiene and health products that people need regardless of the economic conditions and the global situation. Our operational flexibility, with a high proportion of local and regional supply chains and agile pricing, also helps us to be well equipped to meet and navigate the challenges that lie ahead.

Capital Markets Day

On May 7, we hold a Capital Markets Day in Gothenburg, at our largest office and a key center of excellence for the Group. I look forward to, together with members of the executive management team, presenting the initiatives that will accelerate the journey toward our financial targets. A very warm welcome!

Ulrika Kolsrud

President and CEO

Group

Net sales

Net sales decreased 5.1% in the first quarter of 2026 compared with the corresponding period a year ago and amounted to SEK 33,177m (34,976). Excluding currency translation effects, net sales increased SEK 528m. The acquisition of Edgewell's feminine care business in North America increased consolidated net sales by 1.1%.

Organic sales increased 0.4%, driven by higher volumes in Personal Care and Professional Hygiene. Growth was negatively impacted by sales prices, mainly due to lower sales prices in Consumer Tissue.

Growth was high in North America, with positive growth in all business areas with presence in the region. Favorable growth was also reported in Latin America. Growth was negative in Europe, primarily due to lower sales in Consumer Tissue.

Operating profit

The gross margin increased 0.7 percentage points to 33.5% (32.8). The gross margin excl. IAC increased 0.6 percentage points to 33.4% (32.8). Costs of goods sold were lower, mainly due to lower costs for raw materials.

Change in net sales

%	2026:1 vs 2025:1
Total	-5.1
Volume	1.1
Price/Mix	-0.7
Organic growth	0.4
Acquisitions	1.1
Divestments	0.0
Currency translation	-6.6


Savings in costs of goods sold amounted to approximately SEK 130m. Higher volumes offset the negative impact of lower sales prices.

EBITA decreased 6% to SEK 4,448m (4,718) and EBITA excl. IAC decreased 2% to SEK 4,603m (4,706). Excluding currency translation effects, EBITA excl. IAC increased 5%, corresponding to SEK 236m. EBITA margin excl. IAC increased to 13.9% (13.5). Sales and administration costs amounted to 19.5% (19.4), of which marketing costs increased to 5.5% (5.2). Savings amounted to approximately SEK 30m. IAC amounted to SEK -162m (32), of which SEK -118m related to acquisition costs and SEK -54m related to the cost savings program.


Change in EBITA excl. IAC

	SEKm
EBITA excl. IAC 2025:1	4,706
Volume	211
Price/Mix	-207
Cost of goods sold	259
Sales & Admin	-32
Currency translation	-339
Acquisitions & Divestments	5
EBITA excl. IAC 2026:1	4,603


Net sales 2603 by business area




Net sales 2603 by region



Net sales



EBITA excl. IAC



Financial items

Financial items decreased to SEK -250m (-373), mainly on account of lower interest rates. Lower average net debt and exchange rate effects also had a positive impact.

Tax

The tax expense was SEK 1,041m (1,025), corresponding to a tax rate of 26.4% (25.0). The tax expense excl. IAC was SEK 1,060m (1,016), corresponding to a tax rate of 25.8% (24.9).

Profit for the period

Profit for the period was SEK 2,901m (3,083).


Cash flow

Operating cash flow amounted to SEK 4,354m (3,765). The increase compared with a year ago was mainly related to more favorable development in working capital. Net cash flow totaled SEK -621m (1,394). The completion of the acquisition of Edgewell's feminine care business had a negative impact on cash flow of SEK 3,004m. During the quarter, Essity bought back 2,343,615 own Class B shares for a total amount of SEK 612m.

Operating cash flow statement

SEKm	2026:1	2025:1
Operating cash surplus	6,297	6,376
Change in inventories	-172	-868
Change in operating receivables	-478	301
Change in operating liabilities	674	-465
Investments in non-current assets, net	-1,251	-1,133
Restructuring costs, etc.	-538	-280
Investments in operating assets through leases	-178	-166
Operating cash flow	4,354	3,765
Financial items	-250	-373
Income taxes paid	-1,109	-1,222
Other	0	0
Cash flow from current operations	2,995	2,170
Acquisitions of Group companies and other operations	-3,004	–
Cash flow before transactions with shareholders	-9	2,170
Repurchase of own shares	-612	-776
Net cash flow	-621	1,394

Operating cash flow



Financial position

Net debt decreased SEK 2,005m compared with December 31, 2025 and amounted to SEK 24,538m. The decrease is mainly related to revaluation of pension assets and pension obligations. The Group's interest-bearing gross debt amounted to SEK 38,272m (34,669) at the end of the quarter. The average maturity period was 2.9 years (3.3).


Compared with December 31, 2025, working capital decreased to SEK 7,962m, mainly due to an approved but unpaid dividend. Working capital amounted to 6% (4) of net sales.

Equity attributable to owners of the Parent company increased SEK 2,090m compared with December 31, 2025. Profit for the period attributable to owners of the Parent company increased the equity of owners of the Parent company by SEK 2,887m. Net translation effects increased equity by SEK 2,471m. Decided but not paid dividend of SEK 5,956m and the buyback of own shares of SEK 612m reduced equity attributable to owners of the Parent company. The Group's total equity increased SEK 2,121m during the quarter.


Share buyback program

The share buyback program of SEK 3bn, which began on April 24, 2025, was completed on March 19, 2026, when Essity repurchased a total of 11,566,941 Class B own shares for SEK 3bn. As of March 31, 2026, Essity's holdings of own shares correspond to 1.8% of the total number of shares outstanding. The Annual General Meeting on March 26, 2026 resolved to cancel own shares. After the end of the quarter, Essity therefore canceled 11,109,318 Class B own shares.

Net debt



ROCE excl. IAC and ROE excl. IAC



Financial position

	2603	2503	2512
Working capital, SEKm	7,962	5,211	12,237
Capital employed, SEKm	112,699	106,478	112,583
Net debt, SEKm	24,538	26,774	26,543
Debt/equity ratio	0.28	0.34	0.31
Debt payment capacity, %	80	67	74
Net debt/EBITDA	0.97	1.04	1.03
Net debt/EBITDA excl. IAC	0.96	1.02	1.03

Return

%	2026:1	2025:1
ROCE	15.8	16.7
ROCE excl. IAC	16.3	16.7
ROE	13.3	14.6
ROE excl. IAC	14.0	14.5

Change in net debt

SEKm	2603	2503	2512
Net debt at the beginning of the period	-26,543	-30,769	-30,769
Net cash flow	-621	1,394	42
Remeasurements to equity	3,248	1,147	2,423
Investments in non-operating assets through leases	-59	-319	-331
Translation differences	-563	1,773	2,092
Net debt at the end of the period	-24,538	-26,774	-26,543

Health & Medical

- Positive organic sales growth
- High growth in wound care
- Higher margin

Net sales

Net sales increased organically 0.5%, driven by a positive price trend. Volumes were unchanged.

High growth was reported in North America. In Europe, growth was negative.

In Incontinence Products, organic growth was negative primarily due to lower volumes.

Organic growth in Medical Solutions was mainly driven by higher sales prices. Higher volumes also had a positive impact. Growth in wound care was high, while orthopedics also noted good sales development.

EBITA excl. IAC

EBITA excl. IAC declined while EBITA margin excl. IAC increased. The costs of goods sold was slightly higher. Earnings were positively impacted by higher sales prices and slightly lower sales and administration costs.

Currency translation effects had a negative impact on earnings of SEK 87m.



Parts of our TENA range in the North American market were upgraded during the quarter. The new TENA ProSkin® Super Briefs and TENA ProSkin® Ultra Briefs are designed for a secure and comfortable fit and feature improved functionality to keep skin dry.

Change in net sales

%	2026:1 vs 2025:1
Total	-6.3
Volume	-0.1
Price/Mix	0.6

	Organic growth
Acquisitions	0.0
Divestments	0.0
Currency translation	-6.8

Organic sales growth

%	2026:1 vs 2025:1	% of net sales
Incontinence Products Health Care	-0.9	58
Medical Solutions	2.5	42


Financial overview

	2026:1	2025:1	%
Net sales, SEKm	6,499	6,936	-6
Organic sales growth, %	0.5	1.7	
Gross profit margin excl. IAC, %	44.9	44.4	
EBITA excl. IAC, SEKm	1,193	1,231	-3
EBITA margin excl. IAC, %	18.4	17.7	
ROCE excl. IAC, %	14.9	14.7	
Operating cash flow, SEKm	1,080	1,232	-12


Net sales 2603 by region



Net sales



EBITA excl. IAC



Personal Care

- Increased market shares
- Strong growth in Incontinence Products and Feminine Care
- Higher margin

Net sales

Net sales increased organically 4.1%. Volumes performed strongly and sales prices made a positive contribution. The product mix was also favorable, with increased sales of high-margin products in Feminine Care and Baby Care. Market shares increased for more than 60% of branded sales. The acquisition in Feminine Care in North America was consolidated as of February 2 and increased net sales by 4.9%.

Growth was high in North America. Growth was positive in Europe and Latin America.

Incontinence Products and Feminine Care reported high organic growth, primarily driven by increased volumes. In Feminine Care, higher sales prices and a favorable product mix also made a contribution. The Baby Care market remained challenging. Growth in our Baby Care business was somewhat negative, mainly due to lower volumes in Retailer Brands. However, market positions of our leading brand Libero were further strengthened and high growth was reported.

EBITA excl. IAC

EBITA and the EBITA margin excl. IAC increased mainly driven by higher volumes, while contributions were also made by higher sales prices and lower costs of goods sold. Marketing costs were higher. Currency translation effects had a negative impact on earnings of SEK 71m.



In Feminine Care, we strengthened our offering in the rapidly growing segment “period pants” with a range specially designed for teenagers.

Change in net sales

%	2026:1 vs 2025:1
Total	2.5
Volume	3.5
Price/Mix	0.6
Organic growth	4.1
Acquisitions	4.9
Divestments	0.0
Currency translation	-6.5


Organic sales growth

%	2026:1 vs 2025:1	% of net sales
Incontinence Products Retail	5.1	35
Feminine Care	5.6	46
Baby Care	-0.3	19


Financial overview

	2026:1	2025:1	%
Net sales, SEKm	8,180	7,984	2
Organic sales growth, %	4.1	3.0	
Gross profit margin excl. IAC, %	42.5	42.3	
EBITA excl. IAC, SEKm	1,262	1,198	5
EBITA margin excl. IAC, %	15.4	15.0	
ROCE excl. IAC, %	24.7	26.2	
Operating cash flow, SEKm	786	215	266


Net sales 2603 by region



Net sales



EBITA excl. IAC



Consumer Tissue

- Higher volumes in own brands
- Lower sales prices
- Favorable growth in Latin America

Net sales

Net sales decreased organically 3.5% as a result of lower sales prices and volumes.

Good growth was reported in Latin America. The sales trend was negative in Europe.

Volumes were higher in branded sales, and we captured market shares in own brands during the quarter.

EBITA excl. IAC

EBITA and the EBITA margin excl. IAC decreased, mainly due to lower sales prices and volumes. The cost of goods sold was lower. Sales costs were slightly higher. Currency translation effects had a negative impact on earnings of SEK 55m compared with the corresponding period a year ago.



For the first time, coreless household towels was launched. A product that produces less waste. The launch was made on the German market under the leading brand Zewa


Change in net sales

%	2026:1 vs 2025:1
Total	-8.4
Volume	-0.6
Price/Mix	-2.9
Organic growth	-3.5
Acquisitions	0.0
Divestments	0.0
Currency translation	-4.9


Financial overview

	2026:1	2025:1	%
Net sales, SEKm	10,356	11,301	-8
Organic sales growth, %	-3.5	2.7	
Gross profit margin excl. IAC, %	20.7	20.5	
EBITA excl. IAC, SEKm	1,112	1,245	-11
EBITA margin excl. IAC, %	10.7	11.0	
ROCE excl. IAC, %	12.8	14.1	
Operating cash flow, SEKm	1,460	1,442	1

Net sales 2603 by region



Net sales



EBITA excl. IAC



Professional Hygiene

- Higher volumes
- Strong growth in premium products
- High growth in North America

Net sales

Net sales increased organically by 1.9%, primarily driven by higher volumes in North America. The product mix also remained favorable with an increased share of premium products. Sales prices were slightly lower.

High growth was reported in North America and Latin America. In Europe, growth was somewhat negative.

EBITA excl. IAC

EBITA excl. IAC declined while EBITA margin excl. IAC was stable. Higher volumes had a positive impact on earnings. Costs of goods sold were stable. Sales costs were slightly higher in order to drive growth. Currency translation effects had a negative impact on earnings of SEK 139m.



The Tork PeakServe® automatic dispenser is a new addition to the range and a further development of the existing and appreciated Tork PeakServe® dispenser.

Change in net sales

%	2026:1 vs 2025:1
Total	-7.1
Volume	1.8
Price/Mix	0.1
Organic growth	1.9
Acquisitions	0.0
Divestments	0.0
Currency translation	-9.0


Financial overview

	2026:1	2025:1	%
Net sales, SEKm	8,139	8,757	-7
Organic sales growth, %	1.9	0.7	
Gross profit margin excl. IAC, %	31.3	31.0	
EBITA excl. IAC, SEKm	1,311	1,413	-7
EBITA margin excl. IAC, %	16.1	16.1	
ROCE excl. IAC, %	20.4	22.0	
Operating cash flow, SEKm	804	1,054	-24

Net sales 2603 by region



Net sales



EBITA excl. IAC



Other Group information

Sustainability

Sustainability is integrated into Essity's strategy and is a priority, with ambitious Group targets in several areas. The outcome for two of the targets is presented below. More information on these and other targets can be found in Essity's Annual Report.

Science-based emissions targets: 2030 Target: -35% vs 2016

Reduction in absolute greenhouse gas emissions, Scope 1 and 2

2022	2023	2024	2025	Q1 2026*
-17%	-27%	-27%	-27%	-28%

*Outcome for the last 12 months

Sustainable innovations: Target: >50% annually
Percentage leading to social and/or environmental improvements

2022	2023	2024	2025	Q1 2026
68%	85%	87%	80%	81%

During the quarter, Essity was awarded a place on the environmental non-profit organization CDP's prestigious "A List" for its sustainability efforts linked to forests.

Events during the quarter

Discontinued lawsuit against Essity regarding bond loans

On January 8, 2026, Essity announced that the funds that had brought an action against Essity in the English courts regarding bond loans issued by the company had chosen to discontinue their action. The case is therefore closed.

Essity signs EUR 400m loan agreement with EIB

On January 26, Essity announced that it had secured a EUR 400m loan at favorable terms with the European Investment Bank (EIB). The loan has a tenor of 7 years and will support the company's research, development, and innovation initiatives.

Essity completes the acquisition of Edgewell's feminine care business

On February 2, Essity announced that it had completed the acquisition of Edgewell's feminine care business, including the Carefree, Stayfree and o.b. brands in North America and Playtex globally. The total purchase price amounted to USD 339m (approximately SEK 2,994m) on a cash and debt-free basis and was consolidated into Essity's financial statements for the Group as of February 2, 2026.

Change to Essity's Executive Management Team

On March 3, Essity announced that it had appointed Niklas Westin Sundberg as Chief Digital & Information Officer. He will succeed Carl-Magnus Månsson. Niklas took office on April 15, 2026 and is a member of the Executive Management Team.

Essity's 2026 Annual General Meeting

Essity's Annual General Meeting was held on March 26, 2026. The Meeting approved the financial statements for

2025 and resolved on a dividend for the 2025 fiscal year of SEK 8.75 per share. Board members Maria Carell, Annemarie Gardshol, Jan Gurander, Alexander Lacik, Torbjörn Lööf, Katarina Martinson, Bert Nordberg, Barbara M. Thoralfsson and Karl Åberg were re-elected. Jan Gurander was re-elected as the Chairman of the Board. The meeting resolved to reduce the share capital through cancellation of own shares and to increase the share capital through a bonus issue.

Events after the quarter

Essity decides on new share buyback program of SEK 3bn

On April 22, 2026, Essity announced that the Group's Board of Directors had resolved to utilize the authorization granted by the Annual General Meeting on March 26, 2026, and initiate a new program to buy back Class B shares in Essity for SEK 3bn. The program begins no earlier than on May 11, 2026, and extends until the 2027 Annual General Meeting at the latest. The share repurchase will be financed using cash flow from current operations after the ordinary dividend with the ambition to continue with share buybacks over time as a recurring part of Essity's capital allocation. Repurchasing will take place on Nasdaq Stockholm in accordance with the stock exchange's issuer regulations and be implemented in accordance with the EU Market Abuse Regulation (MAR) and the European Commission's Delegated Regulation 2016/1052 (Safe Harbour Regulation).

Stockholm, April 23, 2026
Essity Aktiebolag (publ)

Ulrika Kolsrud
President and CEO

NB: This information is such information that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of Karl Stoltz, Public Relations Director at 07:00 a.m. CET on April 23, 2026.

This report has not been reviewed by the company's auditors.

Financial statements

Condensed consolidated income statement

SEKm	2026:1	2025:1	%	SEKm	2026:1	2025:1
Net sales	33,177	34,976	-5	Earnings attributable to:		
Cost of goods sold	-22,092	-23,502		Owners of the Parent company	2,887	3,069
Items affecting comparability (IAC) - cost of goods sold	24	-10		Non-controlling interests	14	14
Gross profit	11,109	11,464	-3	Profit for the period	2,901	3,083
Gross profit excl. IAC	11,085	11,474	-3	Earnings per share		
Sales, general and administration	-6,482	-6,768		-owners of the Parent company		
Items affecting comparability (IAC) - sales, general and administration	-179	22		Earnings per share before and after dilution effects, SEK	4.23	4.43
Operating profit before amortization of acquisition-related intangible assets (EBITA)	4,448	4,718	-6	Average numbers of shares before and after dilution effects, million	681.9	693.4
Operating profit before amortization of acquisition-related intangible assets (EBITA) excl. IAC	4,603	4,706	-2			
Amortization of acquisition-related intangible assets	-245	-256				
Items affecting comparability (IAC) - acquisition-related intangible assets	-7	20				
Operating profit	4,196	4,482	-6			
Operating profit excl. IAC	4,358	4,450	-2			
Share of profits of associates and joint ventures	-4	-1				
Financial items	-250	-373				
Profit before tax	3,942	4,108	-4			
Profit before tax excl. IAC	4,104	4,076	1			
Income taxes	-1,041	-1,025				
Profit for the period	2,901	3,083	-6			
Profit for the period excl. IAC	3,044	3,060	-1			
Items affecting comparability (IAC) before tax	-162	32				
Items affecting comparability (IAC) after tax	-143	23				
Tax on amortization of acquisition-related intangible assets	72	75				

Consolidated statement of comprehensive income

SEKm	2026:1	2025:1	%
Profit for the period	2,901	3,083	-6
Other comprehensive income for the period			
Items that will not be reclassified to the income statement			
Actuarial gains/losses on defined benefit pension plans	3,250	1,148	
Fair value through other comprehensive income	-2	-1	
Income tax attributable to components in other comprehensive income	-712	-284	
Total	2,536	863	

SEKm	2026:1	2025:1
Items that have been or may be reclassified subsequently to the income statement		
Cash flow hedges:		
Result from remeasurement of derivatives recognized in equity	742	-160
Transferred to profit or loss for the period	222	-16
Translation differences in foreign operations	2,684	-7,080
Gains/losses from hedges of net investments in foreign operations	-196	942
Income tax attributable to components in other comprehensive income	-201	-175
Total	3,251	-6,489
Other comprehensive income for the period, net of tax	5,787	-5,626
Total comprehensive income for the period	8,688	-2,543
Total comprehensive income attributable to:		
Owners of the Parent company	8,657	-2,527
Non-controlling interests	31	-16

Consolidated balance sheet

SEKm	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
ASSETS			
Non-current assets			
Goodwill	38,804	38,124	36,861
Intangible assets	19,478	19,343	18,273
Property, plant and equipment	48,054	45,097	46,308
Right-of-use assets	3,823	4,055	3,752
Investments in associates and joint ventures	307	330	307
Shares and participations	8	8	8
Surplus in funded pension plans	7,811	2,593	4,340
Non-current financial assets	124	221	142
Deferred tax assets	2,067	2,203	2,122
Other non-current assets	898	728	725
Total non-current assets	121,374	112,702	112,838
Current assets			
Inventories	19,395	18,493	18,153
Trade receivables	22,689	22,278	21,332
Current tax assets	1,497	1,446	1,626
Other current receivables	3,780	3,586	3,414
Current financial assets	1,381	2,893	1,266
Non-current assets held for sale	—	76	—
Cash and cash equivalents	10,741	9,767	8,487
Total current assets	59,483	58,539	54,278
Total assets	180,857	171,241	167,116

SEKm	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
EQUITY AND LIABILITIES			
Equity			
Owners of the Parent company			
Share capital	2,350	2,350	2,350
Reserves	7,490	6,768	4,257
Retained earnings including profit/loss for the period	77,875	70,175	79,018
Equity attributable to owner of the Parent company	87,715	79,293	85,625
Non-controlling interests	446	411	415
Total equity	88,161	79,704	86,040
Non-current liabilities			
Non-current financial liabilities	26,331	38,161	31,386
Provisions for pensions	2,284	1,571	2,146
Deferred tax liabilities	7,194	6,699	6,272
Other non-current provisions	304	400	384
Other non-current liabilities	58	516	92
Total non-current liabilities	36,171	47,347	40,280
Current liabilities			
Current financial liabilities	15,980	2,516	7,246
Trade payables	15,127	15,675	14,437
Current tax liabilities	1,671	1,364	1,847
Current provisions	1,016	1,211	1,200
Other current liabilities	22,731 ¹⁾	23,424 ²⁾	16,066
Total current liabilities	56,525	44,190	40,796
Total equity and liabilities	180,857	171,241	167,116

¹⁾ Of this amount, SEK 5,956m represents a liability relating to the dividend for Essity's shareholders paid on April 2, 2026, as decided at the Annual General Meeting on March 26, 2026.

²⁾ Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025, as decided at the Annual General Meeting on March 27, 2025.

Consolidated statement of change in equity

SEKm	Mar 31, 2026	Mar 31, 2025	Dec 31, 2025
Equity attributable to owners of the Parent company			
Value, beginning of the period	85,625	88,314	88,314
Total comprehensive income for the period	8,657	-2,527	5,734
Dividend	-5,956 ¹⁾	-5,711 ²⁾	-5,711
Repurchase of own shares	-612	-776	-3,160
Transferred to cost of hedged investments	1	5	6
Revaluation effect upon acquisition of non-controlling interests	—	-12	442
Value, end of period	87,715	79,293	85,625
Non-controlling interests			
Value, beginning of the period	415	427	427
Total comprehensive income for the period	31	-16	8
Dividend	—	—	-20
Value, end of the period	446	411	415
Total equity, value end of the period	88,161	79,704	86,040

¹⁾ Dividend of SEK 5,956m decided at the Annual General Meeting on March 26, 2026, paid on April 2, 2026.

²⁾ Dividend of SEK 5,711m decided at the Annual General Meeting on March 27, 2025, paid on April 3, 2025.

Consolidated cash flow statement

SEKm	2603	2503
Operating activities		
Operating profit	4,196	4,482
Adjustments for non-cash items ¹⁾	1,999	1,875
Capitalized expenditures to fulfill contracts with customers	-165	-118
Change in provisions relating to restructuring programs, etc.	-271	-143
Cash flow from changes in working capital		
Change in inventories	-172	-868
Change in operating receivables	-478	301
Change in operating liabilities	674	-465
Cash flow from operations	5,783	5,064
Interest paid	-448	-1,011
Interest received	57	117
Other financial items	-44	-32
Income taxes paid	-1,109	-1,222
Cash flow from operating activities	4,239	2,916
Investing activities		
Acquisitions of Group companies and other operations	-2,994	—
Investments in intangible assets and property, plant and equipment	-1,253	-1,144
Paid interest capitalized in intangible assets and property, plant and equipment	-5	-6
Sale of property, plant and equipment	7	17
Purchase and sale of financial assets with short maturities	280	2,863
Cash flow from investing activities	-3,965	1,730

SEKm	2603	2503
Financing activities		
Proceeds from borrowings	1,990	42
Repayment of borrowings	-128	-4,227
Payment of lease liabilities	-266	-289
Change in borrowings with short maturities, etc.	894	-413
Repurchase of own shares	-612	-776
Cash flow from financing activities	1,878	-5,663
Cash flow for the period	2,152	-1,017
Cash and cash equivalents at the beginning of the period	8,487	10,962
Translation differences in cash and cash equivalents	102	-178
Cash and cash equivalents at the end of the period	10,741	9,767

¹⁾ Adjustments for non-cash items

SEKm	2603	2503
Depreciation/amortization and impairment of non-current assets	1,746	1,747
Depreciation of capitalized selling expenses	111	120
Gain/loss on sale of assets	-3	—
Non-cash items relating to restructuring program	0	2
Other	145	6
Total	1,999	1,875

Consolidated cash flow statement, cont.

Reconciliation with consolidated operating cash flow statement

SEKm	2603	2503
Cash flow for the period	2,152	-1,017
Proceeds from borrowings	-1,990	-42
Repayment of borrowings	128	4,227
Payment of lease liabilities	266	289
Change in borrowings with short maturities, etc.	-894	413
Purchase and sale of financial assets with short maturities	-280	-2,863
Net debt in acquired and divested operations	-10	—
Investments in operating assets through leases	-178	-166
Accrued interest, etc.	185	553
Net cash flow according to consolidated operating cash flow statement	-621	1,394

Condensed financial statements, Parent company

Condensed Parent company income statement

SEKm	2603	2503
Administrative expenses	-251	-199
Other operating income	14	-7
Operating loss	-237	-206
Financial items	579	-672
Profit/loss before tax	342	-878
Income taxes	30	16
Profit/loss for the period	372	-862

Parent company statement of comprehensive income

SEKm	2603	2503
Profit/loss for the period	372	-862
Other comprehensive income for the period	—	—
Total comprehensive income for the period	372	-862

Condensed Parent company balance sheet

SEKm	Mar 31, 2026	Dec 31, 2025
Assets		
Intangible assets	0	0
Property, plant and equipment	11	11
Financial non-current assets	176,713	176,680
Total non-current assets	176,724	176,691
Total current assets	873	2,560
Total assets	177,597	179,251
Equity, provisions and liabilities		
Equity		
Restricted equity	2,350	2,350
Non-restricted equity	79,179	85,376
Total equity	81,529	87,726
Untaxed reserves	1,477	1,477
Provisions	795	830
Non-current liabilities	24,924	30,028
Current liabilities	68,872 ¹⁾	59,190
Total equity, provisions and liabilities	177,597	179,251

¹⁾ The Annual General Meeting on March 26, 2026 resolved to distribute SEK 5,956m to Essity's shareholders, which is recognized as a current liability at March 31, 2026.

Notes

Note 1 Accounting principles

This interim report has been prepared in accordance with IAS 34 and recommendation RFR 1 of the Swedish Corporate Reporting Board and RFR 2 for the Parent company. The following amendments to IFRS® Accounting Standards have gained legal force from January 1, 2026. Essity Aktiebolag (publ) applies these amendments, which have not had any material impact on the Group's or the Parent company's financial statements.

- IFRS 9 Financial Instruments and IFRS 7 Financial Instruments: Disclosures have been amended with regard to classification and measurement of some specific financial instruments and disclosures.
- A number of other standards have been amended as part of the IASB's annual improvement process and include clarifications, simplifications, corrections and consistency improvements.

In February 2026, the EU endorsed the new standard IFRS 18 Presentation and Disclosure in Financial Statements, which will take effect from January 1, 2027. During the first quarter of 2026, Essity continued analyzing and identifying effects in the areas described on page 119 of the 2025 Annual Report.

In other respects, the accounting principles and calculation methods applied correspond to those described in Essity's 2025 Annual Report.

Note 2 Risks and uncertainties

Processes for risk management

Essity's Board determines the Group's strategic direction based on recommendations from the Executive Management Team. Responsibility for the long-term, overall management of strategic risks corresponds to the company's delegation structure, from the Board of Directors to the CEO and from the CEO to the Business Unit Presidents. This means that most operational risks are managed by Essity's business units at the local level, but they are centrally coordinated when considered necessary. The tools used for coordination consist primarily of the business units' regular reporting and the annual strategy process, which includes risks and risk management.

Essity's financial risk management is centralized, as is its internal bank for financial transactions conducted by Group companies and the management of the Group's energy risks. Financial risks are managed in accordance with the Group's Finance Policy, which is adopted by Essity's Board and, together with Essity's Energy Risk Policy, provides a management framework. Risks are continuously compiled and monitored to ensure compliance with these guidelines. Essity has also centralized other risk management.

Essity has a staff function for internal audit, which monitors compliance with the Group's policies.

Essity's risk exposure and risk management are described on pages 41–46 in the 2025 Annual Report and in the sections under environmental information and social information on pages 58–60. No significant changes have taken place that have affected the reported risks.

Risks in conjunction with company acquisitions are analyzed in the due diligence processes that Essity carries out prior to all acquisitions. In cases where acquisitions have been carried out that may affect the assessment of Essity's risk exposure, these are described under the heading "Events during the quarter" in the interim or year-end reports.

Ongoing geopolitical tensions, such as the war in Iran and the conflicts in and around the Persian Gulf, contribute to increased economic uncertainty and rising commodity prices. The prices of oil and gas have increased significantly following the outbreak of the war. Changes in prices of commodities such as oil and gas may directly or indirectly affect the Group's financial position and operating profit through higher costs, price increases and reduced purchasing power among customers and consumers.

Note 3 Financial assets and liabilities

Measurement principles and classifications of financial instruments, as described in Essity's 2025 Annual Report, Note E1, were applied consistently throughout the reporting period. Financial liabilities are measured at amortized cost provided they are not part of a fair value hedge when they are recognized at fair value through profit or loss. The fair value of trade receivables, other current and non-current receivables, cash and cash equivalents, trade payables and other current and non-current liabilities is estimated to be equal to their carrying amount.

SEKm	Carrying amount	Fair value	Carrying amount	Fair value	Measurement level ¹⁾
	Mar 31, 2026	Mar 31, 2026	Dec 31, 2025	Dec 31, 2025	
Assets					
Derivatives	1,630	1,630	506	506	2
Non-current financial assets	106	106	106	106	1
Total assets	1,736	1,736	612	612	
Liabilities					
Derivatives	1,540	1,540	1,607	1,607	2
Current financial liabilities ²⁾	14,310	14,310	5,707	5,707	2
Non-current financial liabilities ²⁾	22,575	22,051	27,692	27,192	2
Total liabilities	38,425	37,901	35,006	34,506	

¹⁾ No financial instruments have been classified to level 3.

²⁾ The measurement level refers to liabilities measured at fair value in a hedging relationship.

Note 4 The share

Number of shares

	2026:1	2025:1
Number of shares, end of period	693,054,489	702,342,489
Of which class A-shares	57,200,658	58,973,654
Of which class B-shares	635,853,831	643,368,835
Number of Class B shares held by Essity, end of period	12,349,441	10,070,500
Number of outstanding shares before and after dilution, end of period	680,705,048	692,271,989
Average number of Class B shares held by Essity, end of period	11,190,518	8,981,594
Average number of shares before and after dilution	681,863,971	693,360,895

At the Annual General Meeting on March 26, 2026, a resolution was passed to cancel the company's own shares, which was carried out after the close of the quarter. Following the cancellation of 11,109,318 Class B shares on April 2, 2026, the total number of shares in Essity amounted to 681,945,171.

Note 5 Acquisitions and divestments

On November 12, 2025, Essity announced that it had acquired Edgewell Personal Care's feminine care business, including the brands Carefree, Stayfree and o.b. in North America and Playtex globally. The preliminary purchase price allocation presented in Essity's 2025 Annual Report has subsequently been adjusted based on additional information on the opening balance of the business obtained after completion of the acquisition.

The acquisition strengthens Essity's presence in feminine care in North America and enables expected synergies, and goodwill has thus been recognized. The business has about 500 employees and reported net sales of USD 264m (SEK 2,583m) in 2025.

The purchase price for the assets amounted to USD 339m (SEK 2,994m) as well as the take-over of net debt of SEK 10m. The acquisition supports Essity's strategy to focus on categories that yield a high return and to strengthen the company's market position in the USA, the world's largest hygiene market.

The acquisition was consolidated into Essity's consolidated financial statements from February 2, 2026. From the date of consolidation, reported net sales amounted to SEK 370m, EBITDA to SEK 22m and EBITA to SEK 5m. If the acquisition had been consolidated as of January 1, 2026, net sales would have amounted to SEK 577m, EBITDA to SEK 34m and EBITA to SEK 8m. Acquisition costs amounted to SEK 118m and were recognized as IAC.

Purchase price allocation

	SEKm
Intangible assets	1,099
Property, plant and equipment	602
Operating assets	530
Net debt excluding cash and cash equivalents	-10
Operating liabilities	-85
Fair value of net assets	2,136
Goodwill	858
Consideration transferred	2 994
Consideration transferred	-2 994
Acquired net debt excluding cash and cash equivalents	-10
Acquisition of Group companies and other operations during the period, including net debt assumed	-3 004

Note 6 Use of non-International Financial Reporting Standards (IFRS®) performance measures

Guidelines for Alternative Performance Measures (APMs) for companies with securities listed on a regulated market in the EU have been issued by ESMA (European Securities and Markets Authority). These guidelines are to be applied for APMs not supported under IFRS.

This interim report refers to a number of performance measures not defined in IFRS. These performance measures are used to help investors, management and other stakeholders analyze the company's operations. These non-IFRS performance measures may differ from similarly titled measures among other companies. Essity's 2025 Annual Report, pages 120–124, describes the various non-IFRS performance measures that are used as a complement to the financial information presented in accordance with IFRS. Abbreviations are used in the report for the performance and return measures below.

Abbreviation	Complete expression
EBITA	Operating profit before amortization of acquisition-related intangible assets
EBITDA	Operating profit before depreciation and amortization of property, plant and equipment and intangible assets
IAC	Items affecting comparability
ROCE	Return on capital employed
ROE	Return on equity

Capital employed

SEKm	2603	2503	2512
Total assets	180,857	171,241	167,116
-Financial assets	-20,057	-15,474	-14,235
-Non-current non-interest bearing liabilities	-7,556	-7,615	-6,748
-Current non-interest bearing liabilities	-40,545 ¹⁾	-41,674 ²⁾	-33,550
Capital employed	112,699	106,478	112,583

Working capital

SEKm	2603	2503	2512
Inventories	19,395	18,493	18,153
Trade receivables	22,689	22,278	21,332
Other current receivables	3,780	3,586	3,414
Trade payables	-15,127	-15,675	-14,437
Other current liabilities	-22,731 ¹⁾	-23,424 ²⁾	-16,066
Other	-44	-47	-159
Working capital	7,962	5,211	12,237

¹⁾ Of this amount, SEK 5,956m represents a liability relating to the dividend for Essity's shareholders paid on April 2, 2026, as decided at the Annual General Meeting on March 26, 2026.

²⁾ Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025, as decided at the Annual General Meeting on March 27, 2025.

Note 6 cont.**Net debt**

SEKm	2603	2503	2512
Surplus in funded pension plans	7,811	2,593	4,340
Non-current financial assets	124	221	142
Current financial assets	1,381	2,893	1,266
Cash and cash equivalents	10,741	9,767	8,487
Financial assets	20,057	15,474	14,235
Non-current financial liabilities	26,331	38,161	31,386
Provisions for pensions	2,284	1,571	2,146
Current financial liabilities	15,980	2,516	7,246
Financial liabilities	44,595	42,248	40,778
Net debt	24,538	26,774	26,543

EBITA

SEKm	2026:1	2025:1
Operating profit	4,196	4,482
-Amortization of acquisition-related intangible assets	245	256
-Items affecting comparability (IAC) - impairment of acquisition related intangible assets	7	-20
Operating profit before amortization and impairment of acquisition-related intangible assets (EBITA)	4,448	4,718
EBITA margin (%)	13.4	13.5
-Items affecting comparability (IAC) - cost of goods sold	-24	10
-Items affecting comparability (IAC) - sales, general and administration	179	-22
EBITA excl. IAC	4,603	4,706
EBITA margin excl. IAC (%)	13.9	13.5

EBITDA

SEKm	2026:1	2025:1
Operating profit	4,196	4,482
-Amortization of acquisition-related intangible assets	245	256
-Depreciation/amortization	1,221	1,227
-Depreciation right-of-use asset	269	282
-Impairment	2	3
-Items affecting comparability (IAC) - impairment net	2	-1
-Items affecting comparability (IAC) - impairment of acquisition-related intangible assets	7	-20
EBITDA	5,942	6,229
-Items affecting comparability (IAC) excluding depreciation/amortization and impairment	153	-11
EBITDA excl. IAC	6,095	6,218

Organic sales growth

SEKm	2026:1	2025:1
Organic sales growth	140	743
Acquisitions	388	—
Divestments	—	-10
Exchange rate effect ¹⁾	-2,327	-607
Recognized change	-1,799	126

¹⁾ Consists solely of currency translation effects

Note 7 Segment reporting

Effective January 1, 2026, Essity has implemented an organizational change, simplifying its structure and creating end-to-end accountability. This aims to further enhance customer and consumer focus, while increasing speed, agility and operational efficiency throughout the Group. The change facilitates increased strategic focus on the product categories and segments with the greatest potential for profitable growth. The new organization consists of the business areas Health & Medical, Personal Care, Consumer Tissue and Professional Hygiene, with clear overall responsibility in each business area for innovation, production, marketing and sales. The former Consumer Goods business area has been split into Personal Care and Consumer Tissue. Essity's former global units Global Marketing & Innovation and Global Supply Chain have been integrated into the four business areas. The tables below show parts of the income statement broken down by operating segment: Health & Medical, Personal Care, Consumer Tissue and Professional Hygiene. For additional information, refer to page 25.

SEKm						2026:1
	Health & Medical	Personal Care	Consumer Tissue	Professional Hygiene	Other operations	Total Group
Net sales	6,499	8,180	10,356	8,139	3	33,177
Cost of goods sold	-3,581	-4,707	-8,216	-5,589	1	-22,092
Sales, general and administration	-1,725	-2,211	-1,028	-1,239	-279	-6,482
Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC	1,193	1,262	1,112	1,311	-275	4,603
Amortization of acquisition-related intangible assets	-174	-65	-1	-5	0	-245
Operating profit/loss excl. IAC	1,019	1,197	1,111	1,306	-275	4,358
Items affecting comparability (IAC)	-28	-36	26	-37	-87	-162
Operating profit/loss	991	1,161	1,137	1,269	-362	4,196
Share of results of associates and joint ventures						-4
Financial items						-250
Tax expense for the period						-1,041
Profit for the period						2,901

SEKm						2025:1
	Health & Medical	Personal Care	Consumer Tissue	Professional Hygiene	Other operations	Total Group
Net sales	6,936	7,984	11,301	8,757	-2	34,976
Cost of goods sold	-3,856	-4,609	-8,980	-6,039	-18	-23,502
Sales, general and administration	-1,849	-2,177	-1,076	-1,305	-361	-6,768
Operating profit/loss before amortization of acquisition-related intangible assets (EBITA) excl. IAC	1,231	1,198	1,245	1,413	-381	4,706
Amortization of acquisition-related intangible assets	-193	-57	-1	-5	—	-256
Operating profit/loss excl. IAC	1,038	1,141	1,244	1,408	-381	4,450
Items affecting comparability (IAC)	30	-1	13	-10	—	32
Operating profit/loss	1,068	1,140	1,257	1,398	-381	4,482
Share of results of associates and joint ventures						-1
Financial items						-373
Tax expense for the period						-1,025
Profit for the period						3,083

Note 8 Supplementary information

Restated description of costs for full-year 2025 by business area valid as of January 1, 2026.

Full-year 2025	Group	Health & Medical	Personal Care	Consumer Tissue	Professional Hygiene
Total operating expenses¹⁾, SEKm	119,894	23,253	27,356	38,354	29,561
Sales, general and administration ²⁾	22%	31%	32%	11%	18%
Energy	5%	1%	1%	9%	6%
Transportation and distribution costs	12%	12%	10%	14%	13%
Other costs of goods sold ³⁾	26%	29%	23%	22%	32%
Raw materials and consumables	35%	27%	34%	44%	31%
Of which					
Pulp	10%	6%	6%	20%	5%
Recovered paper	3%	0%	0%	4%	8%
Super absorbents	1%	2%	3%	0%	0%
Non-woven	3%	4%	7%	0%	0%
Other ⁴⁾	18%	15%	18%	20%	18%
Total raw materials and consumables	35%	27%	34%	44%	31%

¹⁾ Excluding items affecting comparability.

²⁾ Sales, general and administration include costs for marketing of 6 percentage points.

³⁾ The two largest items of Other costs of goods sold comprise personnel of 12 percentage points and depreciation/amortization of 4 percentage points.

⁴⁾ The item Other in Raw materials and consumables includes costs for chemicals, packaging material and plastic material.

Information by business area

Net sales

SEKm	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3	2024:2	2024:1
Health & Medical	6,499	6,926	6,883	6,723	6,936	7,417	7,127	7,213	6,842
Personal Care	8,180	7,884	7,927	7,763	7,984	8,411	8,083	8,422	8,090
Consumer Tissue	10,356	10,909	10,656	10,671	11,301	12,061	11,327	11,250	11,248
Professional Hygiene	8,139	8,961	9,183	9,003	8,757	9,923	9,729	9,729	8,686
Other	3	15	-11	25	-2	-7	8	3	-16
Group	33,177	34,695	34,638	34,185	34,976	37,805	36,274	36,617	34,850

Organic sales growth

%	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3	2024:2	2024:1
Health & Medical	0.5	0.7	1.7	0.1	1.7	5.6	2.8	4.5	2.6
Personal Care	4.1	1.5	4.5	3.6	3.0	4.8	4.4	3.7	2.3
Consumer Tissue	-3.5	-4.4	-1.9	2.9	2.7	4.3	2.0	-4.7	-9.0
Professional Hygiene	1.9	-0.8	0.7	0.6	0.7	1.4	-0.8	-3.9	-6.9
Group	0.4	-1.1	0.9	1.9	2.1	3.9	1.9	-0.9	-4.0

EBITA excl. IAC

SEKm	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3	2024:2	2024:1
Health & Medical	1,193	1,296	1,260	1,159	1,231	1,361	1,386	1,472	1,290
Personal Care	1,262	990	1,110	1,120	1,198	1,221	1,261	1,349	1,214
Consumer Tissue	1,112	1,442	1,252	1,248	1,245	1,024	1,024	1,085	1,331
Professional Hygiene	1,311	1,750	1,676	1,525	1,413	1,817	1,812	1,868	1,332
Other	-275	-361	-242	-359	-381	-454	-386	-376	-287
Group	4,603	5,117	5,056	4,693	4,706	4,969	5,097	5,398	4,880

EBITA margin excl. IAC

%	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3	2024:2	2024:1
Health & Medical	18.4	18.7	18.3	17.2	17.7	18.3	19.4	20.4	18.9
Personal Care	15.4	12.6	14.0	14.4	15.0	14.5	15.6	16.0	15.0
Consumer Tissue	10.7	13.2	11.7	11.7	11.0	8.5	9.0	9.6	11.8
Professional Hygiene	16.1	19.5	18.3	16.9	16.1	18.3	18.6	19.2	15.3
Group	13.9	14.7	14.6	13.7	13.5	13.1	14.1	14.7	14.0

Capital employed

SEKm	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3	2024:2	2024:1
Health & Medical	32,430	31,577	32,673	33,352	32,366	34,566	33,112	34,245	34,153
Personal Care	22,593	18,299	18,621	18,405	17,913	18,593	17,238	18,265	18,566
Consumer Tissue	35,059	34,744	35,512	35,442	34,180	36,700	35,322	36,077	36,046
Professional Hygiene	26,347	25,176	25,311	25,850	25,494	25,998	24,501	25,976	25,663
Other	-3,730 ¹⁾	2,787	2,172	2,335	-3,475 ²⁾	3,653	2,784	2,513	2,011
Group	112,699	112,583	114,289	115,384	106,478	119,510	112,957	117,076	116,439

¹⁾ Of this amount, SEK 5,956m represents a liability relating to the dividend for Essity's shareholders paid on April 2, 2026, as decided at the Annual General Meeting on March 26, 2026.

²⁾ Of this amount, SEK 5,711m represents a liability relating to the dividend for Essity's shareholders paid on April 3, 2025, as decided at the Annual General Meeting on March 27, 2025.

ROCE excl. IAC

%	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3	2024:2	2024:1
Health & Medical	14.9	16.1	15.3	14.1	14.7	16.1	16.5	17.2	15.4
Personal Care	24.7	21.5	24.0	24.7	26.2	27.3	28.4	29.3	27.1
Consumer Tissue	12.8	16.4	14.1	14.3	14.1	11.4	11.5	12.0	15.0
Professional Hygiene	20.4	27.7	26.2	23.8	22.0	28.8	28.7	28.9	21.4
Group	16.3	18.0	17.6	16.9	16.7	17.1	17.7	18.5	17.2

Operating cash flow

SEKm	2026:1	2025:4	2025:3	2025:2	2025:1	2024:4	2024:3	2024:2	2024:1
Health & Medical	1,080	1,538	1,471	398	1,232	976	1,674	879	1,330
Personal Care	786	541	1,133	654	215	400	1,822	1,195	952
Consumer Tissue	1,460	1,297	947	506	1,442	714	971	247	1,379
Professional Hygiene	804	1,922	1,880	490	1,054	1,678	2,153	1,538	780
Other	224	-929	-107	-508	-178	-471	-167	-620	-188
Group	4,354	4,369	5,324	1,540	3,765	3,297	6,453	3,239	4,253

Invitation to presentation

President and CEO Ulrika Kolsrud and Executive Vice President and CFO Fredrik Rystedt will present the report at a live webcast and teleconference at 09:00 CET on April 23, 2026.

Link to the live presentation, which can also be viewed afterwards:

<https://essity.videosync.fi/2026-04-23>

Contact information for conference call with the possibility to ask questions:

UK: +44 (0) 33 0551 02 00

USA: +1 786 697 35 01

SWE: +46 (0) 8 505 204 24

Please call in well in advance of the start of the presentation. Indicate: "Essity".

Financial calendar 2026-2027

Capital Markets Day	May 7, 2026
Interim report, Quarter 2, 2026	July 16, 2026
Interim report, Quarter 3, 2026	October 22, 2026
Interim report, Quarter 4, full-year 2026	January 21, 2027
Annual Report 2026	February/March 2027

For additional information

Fredrik Rystedt, Executive Vice President and CFO, tel: +46 (0) 8 788 51 31
Sandra Åberg, Vice President Investor Relations, tel: +46 (0) 70 564 96 89
Per Lorentz, Vice President Corporate Affairs, tel: +46 (0) 73 313 30 55

For more information about Essity, visit essity.com.

Essity is a global, leading hygiene and health company.

Every day, our products, solutions and services are used by a billion people around the world. Our purpose is to break barriers to well-being for the benefit of consumers, patients, caregivers, customers and society. Sales are conducted in approximately 150 countries under the leading global brands TENA and Tork, and other strong brands such as Actimove, Cutimed, JOBST, Knix, Leukoplast, Libero, Libresse, Lotus, Modibodi, Nosotras, Saba, Tempo, TOM Organic and Zewa. In 2025, Essity had net sales of approximately SEK 138bn (EUR 13bn) and employed 36,000 people. The company's headquarter is in Stockholm, Sweden and Essity is listed on Nasdaq Stockholm.

